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Aim: We aimed to explore links between heart rate variability (HRV) and clinical depression 
in patients with acute coronary syndrome (ACS), through a review of recent clinical research 
literature.
Background: Patients with ACS are at risk for both cardiac autonomic dysfunction and clinical 
depression. Both conditions can negatively impact the ability to recover from an acute physi-
ological insult, such as unstable angina or myocardial infarction, increasing the risk for adverse 
cardiovascular outcomes. HRV is recognized as a reflection of autonomic function.
Methods: A narrative review was undertaken to evaluate state-of-the-art clinical research, using 
the PubMed database, January 2013. The search terms “heart rate variability” and “depression” 
were used in conjunction with “acute coronary syndrome”, “unstable angina”, or “myocardial 
infarction” to find clinical studies published within the past 10 years related to HRV and  clinical 
depression, in patients with an ACS episode. Studies were included if HRV measurement and 
depression screening were undertaken during an ACS hospitalization or within 2 months of 
hospital discharge.
Results: Nine clinical studies met the inclusion criteria. The studies’ results indicate that there 
may be a relationship between abnormal HRV and clinical depression when assessed early 
after an ACS event, offering the possibility that these risk factors play a modest role in patient 
outcomes.
Conclusion: While a definitive conclusion about the relevance of HRV and clinical depression 
measurement in ACS patients would be premature, the literature suggests that these measures 
may provide additional information in risk assessment. Potential avenues for further research 
are proposed.
Keywords: autonomic nervous system, depressive disorder, outcomes research, risk 
assessment
Introduction
Relieving the burden of morbidity and mortality in cardiovascular (CV) disease is a 
vital, ongoing public health goal. While great progress has been made in managing 
acute coronary syndrome (ACS), the incidence of coronary events remains high. In 
2010, over 1.1 million hospitalizations in the United States were attributed to ACS, the 
umbrella term for myocardial infarction (MI) or unstable angina (UA).1 Recognition 
and management of CV risk factors promotes tertiary prevention, potentially helping 
patients avoid repeated ACS episodes.
Autonomic nervous system dysfunction2 6 and clinical depression7 10 have been 
associated with a significant risk of adverse CV outcomes in ACS patients. Cardiac 
autonomic physiology, as measured by heart rate variability (HRV), appears to 





have a complex interplay with psychosocial factors.2,11,12 
 Understanding the association of altered HRV and depres-
sion, as a possible means to improve the prognosis of ACS 
patients, has become the focus of recent studies.13 21
Background
Research has linked the human autonomic response to 
threat – increased sympathetic and decreased parasympa-
thetic activity – with a higher risk of sudden cardiac death 
in the presence of MI.3,4,22 UA patients also may have an 
increased risk for adverse CV events.5 HRV serves as a 
quantitative reflection of autonomic nervous system activity 
and has been shown to have potential for risk stratification 
in cardiac patients.2,23 25
Clinical depression also has been linked to adverse CV out-
comes, including death.7 9 Of patients hospitalized for acute 
MI, 30% are reported to have mild-to-moderate depressive 
symptoms, and nearly 20% have major depression.10 The 
mechanisms behind the connection between depression and 
post-MI mortality are not yet clear.26 Study results describing 
the full extent of the role of depression in adverse outcomes 
have been inconsistent.27
In 1988, Carney et al examined depression and HRV 
in stable coronary artery disease and found that HRV was 
lower in the patients with coronary artery disease who were 
depressed than in those who were nondepressed.28 In the 
ensuing years, further research has suggested an adverse 




The primary aim of this review was to examine current research 
findings regarding links between HRV and clinical depression in 
ACS patients, assessed during or soon after hospital  admission. 
The reasons for clinical depression are multifaceted, and the 
underlying physiology is not well understood.26,27  Screening 
for depression in ACS patients is recommended in practice 
guidelines.30,31 The research literature raises a question: Could 
the assessment of HRV in conjunction with depression screen-
ing, potentially during ACS hospitalization or soon afterward, 
offer information to assist in assessing risk? The secondary aim 
of this review was to increase knowledge about HRV and its 
measurement. To address the second aim, the history of HRV 
in relation to ACS, and HRV measurement are discussed in the 
sections preceding the “Results” section. Table 1 provides the 
definitions of the HRV variables.
Design
While several reviews have examined depression and HRV in 
relation to stable coronary heart disease, their early assessment 
in ACS has received little attention. The uniqueness of our nar-
rative review lies in its focus on current studies that measured 
HRV and clinical depression during or within 2 months of 
ACS hospitalization, the time frame typically required for ACS 
patients to move beyond the highly acute phase.31 Our pragmatic 
rationale was that cardiac patients are monitored routinely from 
the time they enter the hospital, and electrocardiographic (ECG) 
monitoring is recommended for at least 24 hours.32 HRV mea-
surements generally can be computed from a continuous ECG 
record.24 In addition to assessing HRV, screening ACS patients 
for clinical depression during their hospitalization could be a 
practical approach to enhancing outcomes after discharge.
Search methods
We searched the PubMed and Web of Science databases to 
identify key clinical studies related to HRV measurement and 
depression, in patients with a recent ACS episode. The search 
terms “heart rate variability” and “depression” were used 
in conjunction with “acute coronary syndrome”, “unstable 
angina”, or “myocardial infarction”. The limiters “human”, 
“adult”, and “English” were used. A publication time frame 
within the preceding 10 years was considered reasonable to 
help ensure state-of-the-art findings.
Search outcomes
After duplicates from the different searches were eliminated, 
12 unique data-based clinical articles related to HRV and 
depression in ACS were examined. Three studies in which 
initial HRV or depression was measured outside the 2-month 
time frame were excluded. Five articles that reported initial 
in-hospital measurements were retained for review, along 
with four studies that described initial HRV and depression 
assessments performed within 2 months of discharge. The 
nine studies that met the inclusion criteria were observational 
or secondary analyses.
Quality appraisal
All the articles in the review focused upon the research 
question. The search and selection methods, inclusion/
exclusion criteria, selection of articles, assessment of 
the quality of the literature, data synthesis, construction 
of a representational schematic (Figure 1), and conclu-
sions were assessed and approved by the authors of this 
review.










































Figure 1 Representation of potential coronary outcome pathways related to mood and heart rate variability after an episode of acute coronary syndrome, ie, unstable angina, 
non-ST elevation myocardial infarction, or ST elevation myocardial infarction.
Table 1 Definitions of frequently used heart rate variability (HRV) measurements
Variable abbreviation HRV definitions (unit of measurement)
Time domain variables: measured using descriptive statistics5,27
Long-term time domain measures
 SDNN Standard deviation (SD) of all normal RR intervals (Normal-Normal [NN]) usually measured over 24 
hours (milliseconds [ms]) (estimates global heart rate variability power; corresponds to total power)
 SDANN Standard deviation of the average normal RR (NN) intervals in all 5-minute segments, usually measured 
over 24 hours (ms) (corresponds to ULF)
 SDNN index Mean of the standard deviations of normal RR (NN) intervals in all 5-minute segments  
over 24 hours (ms) (corresponds to the mean of 5-minute segments of total power)
Short-term time domain measures
 rMSSD (rMSNN) Square root of the mean of squares of the differences between successive normal RR (NN) intervals 
(ms); referred to as rMSNN in the study by Guinjoan et al13 (corresponds to HF)
 pNN50* Percentage of normal RR intervals that are 50 ms different from previous normal RR during 
recording time (%) (corresponds to HF)
Frequency domain variables: measured using spectral analysis5,27
TP* Total power, estimates global power, ie, HF, LF, VLF, and ULF, measured over 24 hours (ms2)
HF* Average of 5-min segments of high frequency power for total recording time (ms2); HF reference  
range 0.15–0.4 Hz
LF* Average of 5-min segments of low frequency power for the total recording time (ms2); LF reference 
range 0.04–0.15 Hz
VLF* Very low frequency power, averages of 5-minute segments measured over the total recording time (ms2); 
VLF reference range 0.003–0.04 Hz
ULF* Ultra low frequency power measured over 24 hours (ms2); ULF reference range 0.003 Hz
LF/HF* Average of 5-min segments of normalized low/high frequency ratio: 
(LF/[total power  VLF] 100) divided by (HF/[total power  VLF] 100)
Nonlinear measures9,29,33–36
ApEn Approximate entropy: measure of randomness or disorder within a system; calculation of the 
logarithmic likelihood that patterns that are similar remain similar in the next incremental comparisons
DFA1 Detrended fractal analysis: short-term fractal scaling exponent calculated over 3–11 beats, averaged 
over 1,000 beats for 24 hours (also known as alpha-1, reported as an exponent value)
SD12 
SD1, SD2
SD12, SD1, and SD2 are derived from the Poincare plot (a scatter plot in which each R–R interval is 
plotted against the next R–R interval). SD12 is the ratio of the dispersion, or standard deviation, of the 
plot’s perpendicular axis, indicating short-term, instantaneous beat-to-beat variance (known as SD1), 
versus the standard deviation of the plot’s diagonal axis, indicating long-term, continuous variance 
(known as SD2) 
Note: While the SD1/SD2 ratio is a nonlinear measurement, SD1 and SD2, calculated individually, are 
linear measurements; SD1 correlates precisely with rMSSD
Notes: The terms “variables,” “measures,” “measurements,” and “indices” are often used interchangeably in referring to HRV. *Natural log transformations are often 
performed for these variables, which usually are not normally distributed. Time domain HRV measurements are based upon the intervals between the “R” waves in the QRS 
complexes (referred to as the RR interval). The QRS complex in the ECG corresponds to depolarization of the ventricles.






The studies were examined closely. Focus was placed on the 
methods sections to discern measurement time frames. 
Table 2 was created to summarize the methods and key 
findings.
Synthesis
The authors of this review discussed the possible relationships 
between ACS patients’ depression, autonomic  dysfunction 
(reflected by HRV), and coronary outcomes. The clinical 
research studies were individually scrutinized and grouped 
into categories. A schematic offering a visual representa-
tion of the relationships between variables was constructed 
(Figure 1).
History of heart rate variability  
in relation to acute coronary syndrome
HRV is based upon the concept of healthy variations in 
the time intervals between sinus beats on the ECG.2,24,25 A 
healthy human heart with an intact autonomic nervous sys-
tem continuously adjusts to internal and external changes; 
thus a heart rate of 60 beats per minute does not mean that 
the heart beats precisely one time per second. Each interval 
varies slightly by milliseconds.33
Researchers have suggested that a decrease in variation 
between sinus beats may be linked to poor CV outcomes. 
The potential clinical significance of HRV in predicting 
outcomes of acute MI was described nearly 50 years ago. 
In 1965, Schneider and Costiloe presented evidence that MI 
patients had less sinus arrhythmia – a component of HRV 
associated with respiration – than did healthy controls.34 In 
1978, Wolf et al reported that among patients admitted to a 
coronary care unit (CCU), those showing evidence of sinus 
arrhythmia upon admission tended to have less mortality 
and better prognosis.35 A seminal 1987 study by Kleiger et al 
demonstrated that low HRV, measured with Holter  recorders 
(ambulatory electrocardiography device) 2 weeks post-MI, 
was independently associated with all-cause mortality during 
31 months of follow-up.3 Since these early findings, research 
supporting the prognostic value of HRV measured after MI 
has expanded4,6 and includes UA patients,5 albeit a causal 
link between altered HRV and poor ACS outcomes has not 
been established.2
Heart rate variability measurement
HRV is a noninvasive measurement that can be obtained from 
ECG monitoring, commonly 24-hour Holter recordings.2,24,25 
Derived from mathematical formulas and computed with 
the aid of computer software, HRV has been used primarily 
as a research tool to assess autonomic function in physi-
ological studies or to examine the cardiac autonomic role in 
risk stratification. One limitation of HRV assessment is that 
sinus rhythm is required to make accurate measurements, 
so patients who have atrial fibrillation or a pacemaker are 
precluded from analysis.24 Despite this constraint, the clinical 
benefits of HRV analysis have become more widely recog-
nized in recent years. The American College of Cardiology 
and American Heart Association recommend education and 
skill in HRV assessment as a prerequisite to competence in 
ambulatory ECG interpretation.36 The American College of 
Cardiology/American Heart Association 2004 practice guide-
lines recommend considering the use of HRV to assess the 
risk of ventricular arrhythmias in the management of patients 
recovering from ST-elevation MI (class IIb, usefulness is less 
well established).30
HRV measurement methods typically fall into three 
categories: time domain; frequency domain; and nonlinear 
dynamics.2,6,24,25 HRV definitions are presented in Table 1.
Time domain HRV uses descriptive statistics to estimate 
the variation in normal sinus RR intervals over time.2,24,25 For 
example, the standard deviation of all normal RR intervals 
over the length of a recording period is called SDNN. There 
are two time domain categories: long-term, usually measured 
over 24 hours, potentially reflecting long cycles, such as cir-
cadian rhythm; and short-term, which can be measured over 
5 10 minutes, potentially reflecting short cycles of beat-to-
beat patterns, such as respiratory or baroreceptor activity.24
Frequency domain measures use spectral density 
 analysis to estimate HRV.37 Frequency domain HRV is 
derived from mathematical algorithms and examines the 
amount of underlying cyclic variation in intervals across 
time (known as variance or power).24,37 The spectrum is 
divided into four bands: high frequency (HF); low fre-
quency (LF); very low frequency (VLF); and ultra-low 
frequency (ULF).2,24,25 HF usually synchronizes with the 
respiratory cycle.38 LF has been associated with changes 
in blood pressure along with fluctuations in sympathetic 
and parasympathetic activity. VLF has been related to 
alterations in body temperature and sleep apnea-related 
heart rate changes.39 ULF has been associated with circa-
dian rhythms.40
The third category, nonlinear dynamic measures, 
takes into account the intricate interactions of physi-
ological  signals.41 They are computed based upon newer 
 bioengineering developments, incorporating theories of 
complexity, chaos, and fractal characteristics.39 44 These 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































methods may capture information about underlying patterns 
of physiological variability (such as how random or corre-
lated the signals are) beyond that which time and frequency 
domain measurements can offer.2,44
Overall, HRV variables appear to reflect the interplay 
between the parasympathetic and sympathetic autonomic 
branches. Associating specific HRV measures solely with 
one or the other autonomic branch is inaccurate.2 For 
example, HF power often is ascribed to respiratory sinus 
arrhythmia, reflecting vagal involvement. While physi-
ological study supports this relationship,38 clinical research 
indicates that this is not true in all patients. Extremely high 
HF values may not necessarily reflect better parasympa-
thetic control of heart rate but rather, might be related 
to disrupted heart rate patterns as a consequence of high 
sympathetic activation or other abnormal, yet to be identi-
fied, phenomena.45
The studies in this review used standard time and 
 frequency domain measures24 or nonlinear dynamic mea-
sures to assess HRV. These measures have been supported 
by previous clinical research43,44 and may have potential for 
clinical applications.46,47
Results
The studies were organized into three groups, based upon 
HRV and depression measurement: 1) differences between 
ACS patients;13 16 2) in association with ACS outcomes;17 20 
3) in relation to inflammation in ACS patients.21
The studies within each group are presented chrono-
logically by publication date. All three HRV measurement 
categories are represented. Depression was diagnosed using 
criteria from the Diagnostic and Statistical Manual of Mental 
Disorders, 4th Edition (DSM-IV). The Hamilton Depression 
Scale (Ham-D), Beck Depression Inventory (BDI), and/or 
patient interviews determined severity. The study summaries 
are presented in Table 2.
Differences in HRV and depression 
between ACS patients
Guinjoan et al prospectively investigated the connection 
between depression and abnormal cardiac autonomic activity 
in 56 patients who had had a recent ACS episode.13
Older ACS patients admitted to the CCU within the 
previous 3 days were recruited. Participants were interviewed 
and given depression scores based upon the Ham-D and 
criteria from the DSM-IV. The 56 patients were categorized 
into two groups: major depression or no depression. For the 








































































































































































































































































































































































































































































































































































































































































































































































































































































HRV and depression in ACS literature review
(550 beats) were obtained using a device that detected 
R-waves and analyzed the signals.
HRV time domain variables that reflected short-term beat-
to-beat variability24 were significantly different between the 
depressed and nondepressed groups, as were the percentage 
of normal RR intervals that were 50 milliseconds different 
from previous normal RR intervals (pNN50) and the root-
mean-square of successive RR differences (rMSNN).13
In the frequency domain, HF power was significantly 
lower in depressed patients and remained so in a mul-
tiple regression with clinical variables (P 0.005). Total 
power, LF, and the LF/HF ratio were not significantly 
different between groups (note that this variable needs 
to be measured over 24 hours, and may not be accurate 
in a short recording, as outlined in Table 1). The authors 
concluded that depression was related to decreased vagal 
cardiac activity in older ACS patients. They noted that 
the sympathetic component could still be a factor but 
was dampened because most participants received beta-
blocking medication.
Research by Vigo et al14 used the same database and 
data collection methods as did Guinjoan et al.13 Two non-
linear dynamics measures and one linear measure were 
compared between groups of depressed and nondepressed 
patients. The two nonlinear variables measured were: 1) 
approximate entropy (ApEn), a measure of randomness or 
disorder within a system,40 and 2) the short-term fractal-
scaling exponent, computed using detrended fluctuation 
analysis (DFA), a method that takes into account chang-
ing conditions over time and is useful in the analysis of 
physiologic signals ( 1 or DFA1).43,44 The linear measure 
was derived from a scatter plot of RR intervals, reflecting 
instantaneous beat-to-beat variation (SD1) (see Table 1 
for definitions).47
SD1 and ApEn were lower and DFA1 was higher in 
depressed compared with nondepressed patients. The authors 
concluded that higher depression severity was related 
to reduced instantaneous beat-to-beat variability (SD1), 
increased randomness (ApEn), and increased fractal correla-
tion properties (DFA1).
Catipović-Veselica et al performed a prospective study 
to examine the prevalence of minor and major depression in 
relation to HRV and clinical characteristics, in 297 hospital-
ized ACS patients.15 The patients underwent 24-hour ECG 
monitoring for HRV measurement; time domain HRV was 
computed. Interviews assessed the presence of major or 
minor depression, using DSM-IV criteria, prior to discharge 
14 18 days after admission.
The time domain variables were significantly lower in 
depressed ACS patients compared with those who were not 
depressed. In addition, these investigators found that depres-
sion was more prevalent in women than men, corresponding 
to the findings of Carney et al.11 However, in contrast to the 
findings of Carney et al, Catipović-Veselica et al found that 
depression was more prevalent in older patients.15
Martens et al sought to examine the extent to which 
acute depressive and anxiety symptoms during hospitaliza-
tion for acute MI could predict 24-hour time and frequency 
domain indices 2 months posthospitalization.16 In this study, 
93 patients were screened for depression and anxiety during 
hospitalization, using the BDI and the State Trait Anxiety 
Inventory for self-report. In all, 82 patients were included in 
the 2-month follow-up visit, at which time they were assessed 
for major depressive disorder (MDD), using the Composite 
International Diagnostic Interview (CIDI); HRV was mea-
sured using 24-hour Holter recordings. Time and frequency 
domain indices were measured.
Nineteen patients were diagnosed with MDD using the 
CIDI; seven were diagnosed with anxiety disorder (three were 
diagnosed with both). Univariate analyses showed that the 
patients with depressive disorder had low SDNN and SDANN 
(P 0.05); in similar analyses, patients with anxiety disorder 
had low rMSSD (P 0.05) (see Table 1 for definitions). In 
multivariable analyses, adjusted for age, sex, previous cardiac 
history, and multivessel disease, anxiety disorder was found to 
be significantly associated with reduced rMSSD and HF power 
(P 0.05), but MDD and HRV were not significantly associated. 
Neither depressive nor anxiety symptoms during hospitalization 
were significant predictors of HRV 2 months later.
HRV and depression in association  
with ACS outcomes
Research by de Guevara et al17 used the same database as did 
Guinjoan et al13 and Vigo et al.14 The investigators aimed to 
determine whether or not depressive symptoms and changes 
in autonomic activity, measured by HRV, are associated 
post-ACS, in older patients. The data were examined at 
two time points: in-hospital and at 6 months post-ACS. Of 
48 patients recruited, 38 had complete follow-up informa-
tion and were included in the analysis. Eight patients died. 
Those who died were significantly more likely to meet 
criteria for major depression at discharge than were patients 
who survived (P 0.039). At 6 months, the survivors with 
depression scores that increased were more likely to have 
lower frequency domain HRV. The researchers concluded 
that cardiac  autonomic function diminished with  worsening 





of patient depressive symptoms at 6 months post-ACS 
episode.
Carney et al hypothesized that HRV mediates the effect 
of depression and designed a study to identify this effect in 
post-MI patients.18 The investigators proposed that the effect 
of HRV would be to mediate the pathway between depression 
and time to death, in ACS patients. The study was a secondary 
analysis of the Enhancing Recovery in Coronary Heart Dis-
ease (ENRICHD), a multicenter  clinical trial, and was built 
upon the authors’ previous work in which autonomic dysfunc-
tion was proposed as a potential physiological mechanism 
linking depression with increased mortality after MI.11,18
Consenting patients were screened 4 weeks after ACS 
hospitalization, using the BDI. Cognitive impairment or 
severe illness constituted exclusion criteria. Patients were 
considered depressed if they met the criteria for major or 
minor depression per the DSM-IV. HRV was measured with 
24-hour Holter recorders. Based upon the authors’ previous 
research, VLF was chosen for the HRV reference measure, 
and a risk score was derived from factors related to all-cause 
mortality, such as age, diabetes, and left ventricular ejection 
fraction.17 Follow-up occurred at 6 and 30 months. All-
cause mortality was the primary end point; in all, 47 out of 
678 patients died.
VLF was significantly lower in depressed compared 
with nondepressed patients in univariate analysis. The 
relationship stayed significant after adjustment with the risk 
score. In analysis of proportional hazard across time, inclu-
sion of VLF was found to alter the risk of mortality related 
to depression. The proportion of the hazard of depression 
related to  mortality risk that could be attributed to VLF was 
27%. The researchers concluded that low HRV is a partial 
mediator of the effect of depression in MI patient survival.
Drago et al sought to determine whether depressed ACS 
patients demonstrate cardiac autonomic dysfunction, as 
measured by HRV, and whether autonomic dysfunction had a 
mediating effect on depression in patients’ 5-year prognosis.19 
The primary end points were recurrence of MI, need for 
revascularization, death, or a composite adverse event 
including any of the three. The investigators consecutively 
enrolled 100 acute MI patients at an Italian medical center. 
Psychiatric interviews and the BDI screened for depression 
7 14 days after admission. DSM-IV diagnoses identified 
patients with MDD or mild-to-moderate  depression. HRV 
was measured using 24-hour Holter monitors prior to 
 discharge. Only SDNN was computed.
SDNN was significantly lower at baseline in patients with 
MDD (P 0.01) or mild-to-moderate depression (P 0.01) 
 compared with those who were not depressed. Over 5 years, 
30 adverse events occurred, including six deaths. In uni-
variate analyses, SDNN was associated with adverse events, 
including death within five years. However, when clinical 
characteristics of the patients were included in a multivari-
ate analysis, SDNN was no longer significantly associated 
with death or other adverse events. Depression was a signifi-
cant contributor to all adverse outcomes, with age and sex 
controlled (P 0.04). The authors concluded that depressed 
post-MI patients exhibited cardiac autonomic dysfunction, 
reflected by decreased SDNN, but this did not appear to be a 
mediator of depression in relation to 5-year outcomes.
Glassman et al studied the influence of sertraline (Zoloft; 
Pfizer, Inc., New York, NY, USA), a selective serotonin 
reuptake inhibitor, and mood improvement on HRV in ACS 
patients, using data from the Sertraline Antidepressant Heart 
Attack Randomized Trial (SADHART), an international, 
multicenter clinical trial.20 The Ham-D was used to measure 
depression severity; patients diagnosed with MDD were 
recruited for continuing participation and then were ran-
domly selected to receive either sertraline or a placebo. HRV 
was assessed 3 weeks after hospitalization (baseline) and at 
 16 weeks, using 24-hour ECG recordings. Frequency domain 
measures, HF, LF, VLF, and ULF, were obtained. Mood 
change was assessed with the Clinical Global Impressions 
score, a scale that measures disease severity and improvement 
attributed to treatment response.48 Paired analyses of ECG 
recordings were performed for 258 patients.
Contrary to previous research showing the recovery of 
HRV indices in the months following MI,49 neither group 
showed an improvement in HRV after 16 weeks. ULF was 
significantly lower in the placebo group (P 0.05), and LF 
was significantly lower in the sertraline group (P 0.05). 
However, when the two groups were compared with each 
other, ULF was significantly higher in the sertraline group 
because ULF was exceptionally low in the placebo group. 
Therefore, higher HRV was associated with the administra-
tion of sertraline and better mood. In addition, comparison 
of patient mood, independent of treatment, showed that 
mood improvement was closely associated with higher LF 
power, but this did not reach statistical significance. Low LF, 
in patients whose mood did not improve, was the primary 
driver in this association. The investigators concluded that 
depression impairs HRV recovery after MI.
HRV and depression in relation  
to inflammation in ACS patients
Frasure-Smith et al investigated connections between HRV, 
inflammation, and depression. Resting measures of three HRV 
indices (SDNN, HF, and LF, measured in 20-minute ECG 
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recordings) and two inflammatory biomarkers (interleukin 
[IL]-6 and C-reactive protein) were examined in relation to the 
level of depressive symptoms in 682 post-ACS patients.21 The 
data were originally collected for the Epidemiological Study of 
Acute Coronary Syndromes and Pathophysiology of Emotions 
(ESCAPE).50 Depressive symptoms were measured using the 
BDI, and patients were assessed for MDD in interviews. HRV 
indices and inflammatory markers were obtained once during 
a follow-up visit 2 months after hospitalization.
The patients were categorized as depressed or 
nondepressed; a total of 47 met criteria for MDD. Analysis of 
the HRV and depressive symptoms did not reveal significant 
associations. However, SDNN, LF, and HF were significantly 
correlated with IL-6 in univariate analysis and remained sig-
nificant when adjusted with clinical  factors (such as age, sex, 
and previous MI). All three HRV variables were significantly 
related to C-reactive protein in  univariate analysis; SDNN 
remained significant in the multivariate model (P 0.044). The 
correlations between HRV and the inflammatory markers, 
especially C-reactive protein, became stronger in association 
with greater depression. In the patients with higher depres-
sion scores, HRV accounted for 4% 5% of the variance in 
C-reactive protein in the multivariate analysis. The authors 
concluded that HRV and inflammatory markers are elevated 
in association with post-MI patient depression.
Discussion
While several study results point toward the possibility of a 
relationship between HRV and depression in ACS patients, 
differences in design produced a range.
The findings from the first group of studies suggest a 
relationship between HRV and depression during an ACS 
episode. However, operational definitions and measurement 
methods varied, so drawing a definitive conclusion about 
significant relationships is thorny. While DSM-IV criteria 
identified depression in all the studies, the defining variable 
ranged from mild-to-moderate13,14 to MDD.15 Regarding HRV, 
Guinjoan et al and Vigo et al14 used 5 10 minute supine 
recordings;13 Catipović-Veselica et al and Martens et al 
examined 24-hour ambulatory recordings.15,16
A closer look at the findings of Vigo et al may provide 
insight into nonlinear dynamics. The researchers’ results 
contrast with those of Kop et al,51 who used 24-hour ECG 
recordings to determine that DFA1 tended to be lower in older 
depressed adults; DFA1 1.0 was associated with a higher 
risk of CV mortality over 15 years. Mäkikallio et al examined 
the relationship between nonlinear dynamic indices and sud-
den cardiac death.44 These investigators found that low DFA1 
predicted cardiac death in patients 65 years of age. The 
risk of dying was 2.5 times greater in patients with DFA1 
1.0 compared with those with higher values.3 In addition, 
Mäkikallio et al found no significant difference in ApEn 
between patients with poor outcomes and those who were 
event-free. Stein et al also examined nonlinear measures of 
HRV.45–47 Stein et al found that low DFA1 was associated 
with greater mortality risk in community-dwellling adults 
65 years.47 The disparities between the findings of Vigo 
et al and those of other researchers’ raises questions. Again 
differences in design and methods may explain the seemingly 
opposite results. Mäkikallio et al and Stein et al used 24-hour 
as opposed to 5- to 10-minute recordings, to examine the rela-
tionship between 10-year outcomes and HRV in different 
populations. However, examination of clinical depression was 
not the primary focus in either Mäkikallio et al’s44 or Stein 
et al’s47 studies.
Tulppo et al showed that in healthy subjects, DFA1 
could be altered in opposite directions, depending upon 
the type of exposure – cold face immersion (the mea-
sure decreased) or cold hand immersion (the measure 
increased). The researchers concluded that DFA1 captures 
a dynamic interplay between parasympathetic and sympa-
thetic activity.43
The value of the work of Vigo et al may be in bringing 
attention to HRV nonlinear dynamics. According to Seely and 
Macklem, ApEn, the entropy variable, reflects the Second 
Law of Thermodynamics, namely that entropy or randomness 
increases in a system over time.40 High ApEn is associated 
with increased randomness, and low ApEn, as found in the 
study of Vigo et al, may reflect reduced randomness,20 which 
could translate to less movement or even gridlock, mirroring 
a clogged system or a clotted vessel.
While the studies by Martens et al and Catipović-Veselica 
et al appear to come to different conclusions about the associa-
tion of HRV and depression, the univariate findings were simi-
lar. Both researchers found significant associations between 
time domain HRV variables and the diagnosis of depression 
measured within the same time frame.15,16 Martens et al went 
a step further by using a multivariate approach to assess the 
relationship; however, the lack of significant results could have 
been due to the small sample, as the authors noted.
In the second group of studies, de Guevara et al found 
evidence to indicate that depression and HRV may vary in 
association with each other post-ACS,17 potentially providing 
background for Carney et al18 and Drago et al19 to examine the 
mediating role of HRV on depression in mortality outcomes. 
Exactly how depression contributes to post-MI mortality 
remains unclear. Altered cardiac autonomic function, pos-
sibly due to the activation of sympathetic fibers and vagal 





withdrawal, may be one explanation. However, Carney et al 
and Drago et al came to different conclusions about the role 
of HRV in mediating the effect of depression on mortality. 
While Carney et al estimated that HRV accounts for approxi-
mately 25% of the effect of depression on mortality, Drago 
et al found that a low SDNN was associated with higher 
incidence of adverse events, including mortality, but was not 
a significant contributor in mediating the effect of depression 
on mortality.19 The differences may partially be attributed to 
methodology. Glassman et al found that decline in cardiac 
autonomic functioning post-ACS might be tempered by an 
appropriate mood-enhancing intervention.20 The underpinning 
for this finding is unclear, but the presence of the association 
may have promising implications for future treatments.
In the last study category, Frasure-Smith et al suggested 
the possibility of a mediating effect between HRV and inflam-
mation in depressed ACS patients.21 The investigators built 
upon their previous work examining post-MI depression,7 
and their findings were consistent with other studies sug-
gesting a relationship between higher levels of inflammatory 
markers and reduced vagal activity, reflected by low HRV 
measurements.51 53
While the extent of each patient’s hazard may vary, an 
ACS diagnosis increases the risk of future adverse events.30,31 
Considering the study findings in this review as a whole, 
there is a possibility that depression and disrupted HRV may 
heighten this risk, while interventions leading to improved 
mood and healthy HRV may lower the risk and improve 
long-term outcomes.
Figure 1 represents possible relationships, suggesting 
that:
Assessment for depression and/or disrupted HRV, 
among the myriad of social, psychological, and physi-
ological risks, may aid the identification of higher risk 
ACS patients.
Inflammation, represented by inflammatory markers, may 
play a role in a potential relationship between HRV and 
depressive symptoms.
Interventions leading to improved mood and/or more 
normal HRV might offer additional guidance to help 
move patients toward better coronary outcomes.
The underlying mechanisms (including inflammation) by 
which depression and disrupted HRV potentially impact 
acute coronary syndrome outcomes remain an open 
question.
The variety of HRV measurement methods makes it 
impossible to directly compare the findings in these different 
studies. There is need for a common language, meaningful 
to bioengineers and clinicians alike, to help advance the 
validity and reliability of measurements. For example, Vigo 
et al described an association between depression and a 
“decreased complexity of the interbeat time series,”14 but the 
most meaningful point for advanced practice nurses and other 
practitioners is that the measurement may reflect poor cardiac 
autonomic integration. Furthermore, the precise physiology 
that a specific HRV parameter represents cannot be deter-
mined, and no single HRV measure can be considered ideal. 
Whether the different HRV variables refer to parasympathetic 
or sympathetic function, both, or other underlying physiology 
(for example, neuroendocrine changes) remains obscure.2
While investigators have sought to establish a “gold 
standard” for HRV, there remains inconsistency regarding 
the best approach. Kotecha et al used 5-minute HRV as a 
noninvasive marker to identify patients with obstructive 
coronary artery disease. These researchers measured HRV 
in the frequency domain and concluded that the 5-minute 
HRV test was clinically useful as a risk stratification tool.54 
Recently, the recording time period of five minutes was used 
as a “gold standard” in studies to determine the accuracy of 
HRV derived from photoplethysmography.55,56
Additional research indicates that measurement of HRV 
in association with clinical depression may be useful in other 
populations, lending support for measurement in ACS. For 
example, patients with decompensated heart failure have been 
another focus of interest. In a study by Guinjoan et al, HRV was 
measured in heart failure patients who had had an MI, using 
short-term (5-minute) recordings. Frequency domain variables 
were successfully measured, and an  association between abnor-
mal HRV and depressive symptoms was found.57
Nonetheless, since the landmark study linking HRV with 
outcomes of myocardial infarction by Kleiger et al in 1987,3 
research using 24-hour Holter recordings to obtain ECG mark-
ers of autonomic function has continued to be prevalent.58 
Twenty-four-hour recordings, in which HRV can be averaged 
over 5-minute increments, have the potential to allow risk 
assessment with both short-term and long-term measurements. 
In addition, one study of MI patients suggested the ability to 
continuously monitor patient ECG over 24 hours, starting from 
the time they arrive in the Emergency Department, may be a 
reasonable approach for assessing autonomic function.59
The variety of methods employed for measuring depres-
sion presents another challenge, by limiting systematic 
comparability of the studies in this review. While all used 
DSM-IV criteria and interviews, four studies added the 
BDI,16,18,19,21 and four used the Ham-D.13,14,17,20 One study used 
the CIDI,16 and another reported assessment for depression 
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in interviews only.15 The studies also varied in their defini-
tion of depression. Like HRV, results for depression can vary 
widely depending upon methodology.9 Across studies, sample 
sizes ranged widely, from 3,816 to 68,220 participants. 
Five studies analyzed data for 100 ACS patients,13,14,16 18 
possibly resulting in low statistical power and, leaving true 
differences undetected.
Could HRV assessed during ACS hospitalization offer 
information in conjunction with depression screening to assist 
in assessing risk after an episode of ACS?
The evidence presented here is modest and in some 
cases, conflicting. Besides inflammation,21,51 53 additional 
factors associated with HRV or clinical depression need to 
be considered as possible confounders, such as age,11,15,55,56 
sex,11,15.60,61 genetics,62 and comorbidities.11 Another attenu-
ating factor is the administration of medications, such as 
beta blockers, which are widely used in the treatment of 
ACS. Beta blockers can modulate the sympathetic response 
of patients in distress,63 and this factor needs to be con-
sidered in HRV interpretation. Other medications, such 
as benzodiazepines, also may play a role in the autonomic 
response and need to be considered in assessing HRV 
measurements.64 Therefore, drawing a definitive conclusion 
about the viability of HRV measurement in conjunction with 
clinical depression during an acute phase of ACS would be 
premature.
Conclusion
The underlying interaction between HRV and depression 
remains elusive, but the possibility of the two relating to 
each other in ACS with incremental impact on patients’ 
prognosis has not been ruled out. Employing a multidimen-
sional approach, the inclusion of early HRV measurement 
along with depression screening in risk assessment for ACS 
patients might be practical for discharge planning and worthy 
of further study.
Limitations of this review
This review focused on measurement as close as possible 
to the acute event, considering that obtaining measurements 
in the hospital during cardiac monitoring might be a practical 
approach. A small body of literature was reviewed, and only 
five studies performed measurements in the hospital, three 
of which measured HRV and depression in the same sample 
of patients.13,14,17 Evidence for measurement in patients with 
stable coronary artery disease, and support for best timing 




There may be a relationship between HRV and depres-
sion in ACS patients, possibly reflecting a disruption of 
autonomic cardiac function.
Worse outcomes may be associated with depression and 
disrupted HRV in ACS patients.
HRV may act as a mediator between depression and 
mortality in ACS patients.
Improved HRV and enhanced mood may be related.
Inflammation may play a role in these relationships.
Future directions
Improving outcomes for ACS patients is an essential component 
of tertiary prevention. Early identification of ACS patients with 
severely disrupted HRV and/or depression may help target those 
who need the most recovery assistance. The aims of future 
research might include the consolidation of similar studies, to 
calculate an effect size of HRV differences between clinically 
depressed and nondepressed ACS patients over time. Additional 
study of possible mediating factors, including the role of inflam-
mation, might be productive. Further exploration of nonlinear 
dynamic variables may also be warranted. Prospective studies 
are needed. Finally, randomized clinical trials comparing the 
outcomes of patients receiving early HRV measurement and 
depression screening versus usual care could help establish 
whether or not adding HRV measurement to bedside monitoring, 
along with depression screening, could be clinically useful to 
enhance the assessment of long-term risk in ACS patients.
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